Eileen Wrabel

Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab

Otto Metzger, Giuseppe Viale, Shayna Stein et al. · Cancer Discovery · 2021 · 240 citations · Full text

Medicine, Cancer Biology, Oncology +15

HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.

Otto Metzger, Giuseppe Viale, Lorenzo Trippa et al. · Journal of Clinical Oncology · 2019 · 82 citations

Medicine, Oncology, Pharmacology +17

Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial

Jorge Gómez Tejeda Zañudo, Romualdo Barroso‐Sousa, Esha Jain et al. · Nature Communications · 2024 · 28 citations · Full text

Medicine, Oncology, Pharmacology +17

SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer

Ana C. Garrido-Castro, Se Eun Kim, Jennifer Desrosiers et al. · Annals of Oncology · 2024 · 26 citations

Medicine, Oncology, Pharmacology +17

Pathogen-inspired drug delivery to the central nervous system

Rebecca L. McCall, Joseph Cacaccio, Eileen Wrabel et al. · Tissue Barriers · 2014 · 24 citations · Full text

Pharmacy, Neuroscience, Pharmaceutics +17